The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.b

Pneumonitis (ILD), acute and/or severe (may cause ARDS)

Publications

Tsubata Y, Hamada A, Sutani A, Isobe T

Erlotinib-induced acute interstitial lung disease associated with extreme elevation of the plasma concentration in an elderly non-small-cell lung cancer patient.

Journal of cancer research and therapeutics 2012 Jan-Mar;8;154-6 — 2012 Jan-Mar — 154-6

Onal C, Abali H, Koc Z, Kara S

Radiation recall pneumonitis caused by erlotinib after palliative definitive radiotherapy.

Onkologie 2012;35;191-4 — 2012 — 191-4

ter Heine R, van den Bosch RT, Schaefer-Prokop CM, Lankheet NA, Beijnen JH, Staaks GH, van der Westerlaken MM, Malingré MM, van den Brand JJ

Fatal interstitial lung disease associated with high erlotinib and metabolite levels. A case report and a review of the literature.

Lung cancer (Amsterdam, Netherlands) 2012 Mar;75;391-7 — 2012 Mar — 391-7

Del Castillo Y, Espinosa P, Bodí F, Alcega R, Muñoz E, Rabassó C, Castander D

Interstitial lung disease associated to erlotinib treatment: a case report.

Cases journal 2010 Feb 12;3;59 — 2010 Feb 12 — 59

Taj A, Kanjwal S, Hammersley JR

New-onset acute interstitial lung disease after treatment with erlotinib in a patient with metastatic squamous cell carcinoma of the lung.

American journal of therapeutics 2011 Jan;18;e19-21 — 2011 Jan — e19-21

Kubota K, Nishiwaki Y, Tamura T, Nakagawa K, Matsui K, Watanabe K, Hida T, Kawahara M, Katakami N, Takeda K, Yokoyama A, Noda K, Fukuoka M, Saijo N

Efficacy and safety of erlotinib monotherapy for Japanese patients with advanced non-small cell lung cancer: a phase II study.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2008 Dec;3;1439-45 — 2008 Dec — 1439-45